Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.
Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.
Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.
Allosteric modulators are on the cutting edge of small molecule drug discovery, and therefore, are generating a great deal of excitement among researchers. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Since orthosteric modulators need to compete with natural ligands, they require higher doses, raising safety issues. Allosteric modulators do not compete and may therefore be effective at lower, safer doses.
Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress will highlight many key developments in the field. Conference attendees will come away with a better understanding of the following topics:
- Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
- Dualsteric GPCR testing
- Allosteric modulation of GPCRs and transporters for the treatment of depression
- Structure-function approaches to understanding allosteric modulation of GPCRs
- Allosteric modulation of purine receptors
- Discovery of small molecule GPCR modulators
- Muscarinic receptors/GPCRs in endocrine and central nervous systems
- Morpheeins as a new pathway for allosteric drug discovery
- Allosteric proteins and the concept of allosteric modulators
Speakers at this year’s congress include:
- P. Jeffrey Conn, Ph.D., Director, Vanderbilt Program in Drug Discovery, Lee E. Limbird Professor of Pharmacology, Vanderbilt University Medical Center
- Patrick M. Sexton, Ph.D., Professor of Pharmacology, Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology, Monash University
- Jean-Pierre Changeux, Ph.D., Professor, Institut Pasteur
- Charlotte Keywood, MD, Chief Medical Officer, Addex Pharmaceuticals
- Connie Sanchez, Ph.D., Vice President Neuroscience, Lundbeck Research USA
- Prof. Dr. Klaus Mohr, Chairman, Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn
Kenneth A. Jacobson, Ph.D., Acting Chief, Laboratory of Bioorganic Chemistry, National Institutes of Health
Robert Lütjens, Ph.D., Head of Core Biology, Addex Pharmaceuticals
Marlene A. Jacobson, Ph.D., Senior Investigator, Merck Research Labs
Jurgen Wess, Ph.D., Chief, Molecular Signaling Section, National Institutes of Health, NIDDK
For more information about this conference, please visit www.allostericmodulatorcongress.com/ or call 1-312-244-3703.
# # #
Read the full story at http://www.prweb.com/releases/2009/11/prweb3154864.htm.
Copyright©2009 Vocus, Inc.
All rights reserved